How much did respiratory medicine sales reach in December 2025 in India?

Respiratory medicine sales in India reached a record Rs 1,950 crore in December 2025.

What types of drugs contributed most to the December 2025 sales surge?

Anti-asthma and COPD medications formed the majority of the sales, totaling nearly Rs 3,500 crore during the October-December quarter.

Is the rise in respiratory illnesses linked to air pollution across India?

Yes, medical experts and market data indicate a strong link between air pollution and increased respiratory illnesses, with sales trends visible across multiple regions.

Home / Health / Pollution Fuels Medicine Sales Surge Past Rs 1,950 Crore

Pollution Fuels Medicine Sales Surge Past Rs 1,950 Crore

12 Jan

•

Summary

Respiratory medicine sales hit a record Rs 1,950 crore in December 2025.
Sales of anti-asthma and COPD drugs contributed significantly to this rise.
This trend is observed across multiple regions, indicating a national health issue.

Pollution Fuels Medicine Sales Surge Past Rs 1,950 Crore

Respiratory medicine sales in India reached an unprecedented high of Rs 1,950 crore in December 2025, signaling a troubling rise in pollution-related health issues. This figure represents a substantial increase compared to previous years, with sales in October-December 2025 also showing significant growth. Anti-asthma and COPD medications were the primary drivers of this surge, indicating the severe impact of poor air quality.

The escalating sales reflect a growing public health concern, with medical experts noting a direct correlation between increased air pollution and respiratory ailments. Medications like Foracort, commonly used for asthma, have seen a marked rise in demand during the winter months. This trend is not confined to a single area, with multiple regions experiencing double-digit growth.